keyword
MENU ▼
Read by QxMD icon Read
search

Pca3

keyword
https://www.readbyqxmd.com/read/29260633/two-stage-classifiers-that-minimize-pca3-and-the-psa-proteolytic-activity-testing-in-the-prediction-of-prostate-cancer-recurrence-after-radical-prostatectomy
#1
Daniel R Jeske, Jenifer A Linehan, Timothy G Wilson, Mark H Kawachi, Kristina Wittig, Katarzya Lamparska, Camille Amparo, Rosa Mejia, Fang Lai, Dimitra Georganopoulou, Steven S Smith
INTRODUCTION: Early biochemical recurrence after prostate cancer surgery is associated with higher risk of aggressive disease and cancer specific death. Many new tests are being developed that will predict the presence of indicators of aggressive disease like early biochemical recurrence. Since recurrence occurs in less than 10% of patients treated for prostate cancer, validation of such tests will require expensive testing on large patient groups. Moreover, clinical application of the validated test requires that each new patient be tested...
December 2017: Canadian Journal of Urology
https://www.readbyqxmd.com/read/29203868/a-microsatellite-repeat-in-pca3-long-non-coding-rna-is-associated-with-prostate-cancer-risk-and-aggressiveness
#2
John Lai, Leire Moya, Jiyuan An, Andrea Hoffman, Srilakshmi Srinivasan, Janaththani Panchadsaram, Carina Walpole, Joanna L Perry-Keene, Suzanne Chambers, Melanie L Lehman, Colleen C Nelson, Judith A Clements, Jyotsna Batra
Short tandem repeats (STRs) are repetitive sequences of a polymorphic stretch of two to six nucleotides. We hypothesized that STRs are associated with prostate cancer development and/or progression. We undertook RNA sequencing analysis of prostate tumors and adjacent non-malignant cells to identify polymorphic STRs that are readily expressed in these cells. Most of the expressed STRs in the clinical samples mapped to intronic and intergenic DNA. Our analysis indicated that three of these STRs (TAAA-ACTG2, TTTTG-TRIB1, and TG-PCA3) are polymorphic and differentially expressed in prostate tumors compared to adjacent non-malignant cells...
December 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29198331/biomarkers-in-prostate-cancer-current-clinical-utility-and-future-perspectives
#3
REVIEW
Alexander Kretschmer, Derya Tilki
Current tendencies in the treatment course of prostate cancer patients increase the need for reliable biomarkers that help in decision-making in a challenging clinical setting. Within the last decade, several novel biomarkers have been introduced. In the following comprehensive review article, we focus on diagnostic (PHI®, 4K score, SelectMDx®, ConfirmMDx®, PCA3, MiPS, ExoDX®, mpMRI) and prognostic (OncotypeDX GPS®, Prolaris®, ProMark®, DNA-ploidy, Decipher®) biomarkers that are in widespread clinical use and are supported by evidence...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29175542/defining-a-cohort-of-men-who-may-not-require-repeat-prostate-biopsy-based-on-pca3-score-and-mri-the-dual-negative-effect
#4
Nathan Perlis, Thamir Al-Kasab, Ardalan Ahmad, Estee Goldberg, Kamel Fadak, Rashid Sayid, Antonio Finelli, Girish Kulkarni, Rob Hamilton, Alexandre Zlotta, Sangeet Ghai, Neil Fleshner
PURPOSE: Prostate Cancer (PCa) overdiagnosis and overtreatment is a concern for clinicians and policy makers. Multiparametric MRI (mpMRI) and the PCA3 urine test select for clinically significant cases. We explore how well the tests perform in combination for men with previous biopsies. MATERIALS AND METHODS: We collected clinicopathologic data from all patients with a PCA3 test from 2011 to June 2016 in accordance with ethics committee approval. This included patients on active surveillance (AS) for low-risk PCa and those without PCa with previous negative biopsies and suspicion of occult disease...
November 23, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29144945/re-association-between-combined-tmprss2-erg-and-pca3-rna-urinary-testing-and-detection-of-aggressive-prostate-cancer
#5
Samir S Taneja
No abstract text is available yet for this article.
December 2017: Journal of Urology
https://www.readbyqxmd.com/read/29115578/characterization-of-prostate-cancer-cell-progression-in-zebrafish-xenograft-model
#6
Wei Xu, Brittany A Foster, Mackenzie Richards, Kenneth R Bondioli, Girish Shah, Christopher C Green
Early diagnosis of prostate cancer (PCa) is critical for the application of efficient treatment to PCa patients. However, the majority of PCas remains indolent from several months to several years before malignancy. Current diagnosis methods have limitations in their reliability and are inefficient in time cost. Thus, an efficient in vivo PCa cell xenograft model is highly desired for diagnostic studies in PCas. In the present study we present a standardized procedure to create a PCa cell xenograft model using zebrafish (Danio rerio) as the host...
January 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29107268/whom-to-biopsy-prediagnostic-risk-stratification-with-biomarkers-nomograms-and-risk-calculators
#7
REVIEW
Stacy Loeb, Hasan Dani
This article describes markers used for prostate biopsy decisions, including prostrate-specific antigen (PSA), free PSA, the prostate health index, 4Kscore, PCA3, and ConfirmMDx. It also summarizes the use of nomograms combining multiple variables for prostate cancer detection.
November 2017: Urologic Clinics of North America
https://www.readbyqxmd.com/read/29104903/biomarkers-for-prostate-biopsy-and-risk-stratification-of-newly-diagnosed-prostate-cancer-patients
#8
Stacy Loeb
Introduction: Many new markers are now available as an aid for decisions about prostate biopsy for men without prostate cancer, and/or to improve risk stratification for men with newly diagnosed prostate cancer. Methods: A literature review was performed on currently available markers for use in decisions about prostate biopsy and initial prostate cancer treatment. Results: Although total prostate-specific antigen cutoffs were traditionally used for biopsy decisions, PSA elevations are not specific...
July 2017: Urology Practice
https://www.readbyqxmd.com/read/29037514/re-association-between-combined-tmprss2-erg-and-pca3-rna-urinary-testing-and-detection-of-aggressive-prostate-cancer
#9
David G McLeod, Gyorgy Petrovics
No abstract text is available yet for this article.
October 13, 2017: European Urology
https://www.readbyqxmd.com/read/28972698/prognostic-value-of-urinary-pca3-during-active-surveillance-of-low-risk-prostate-cancer-in-patients-receiving-5%C3%AE-reductase-inhibitors
#10
Vincent Fradet, Paul Toren, Molière Nguile-Makao, Michele Lodde, Jérome Lévesque, Caroline Léger, André Caron, Alain Bergeron, Tal Ben-Zvi, Louis Lacombe, Frédéric Pouliot, Rabi Tiguert, Thierry Dujardin, Yves Fradet
OBJECTIVES: To determine the clinical performance of the urinary PCA3 test to predict the risk of Gleason grade re-classification among men receiving a 5α-reductase inhibitor during active surveillance for prostate cancer. PATIENTS AND METHODS: Patients with low-risk prostate cancer were enrolled in a prospective Phase II study of active surveillance complemented with prescription of a 5ARI. Repeat biopsy was performed within the first year and annually according to physician and patient preference...
October 3, 2017: BJU International
https://www.readbyqxmd.com/read/28938580/diagnostic-significance-of-urinary-long-non-coding-pca3-rna-in-prostate-cancer
#11
Tao Wang, Xiangyun Qu, Jiajia Jiang, Peng Gao, Dingding Zhao, Xueqi Lian, Xiaohua Li
Prostate cancer antigen 3(PCA3) is a long non-coding RNA, which was found increased expression in CaP patients than healthy individual. In this study, the individual nucleic acid of PCA3 and PSA was recombinant expressed as a reference reagent, and a quantitative RT-PCR with TaqMan assay was developed to examine the copies of PCA3 and PSA gene in urine. The results showed that the area under the receiver operating characteristic curve (AUROC) was 0.717, 0.444 and 0.916 for the number of PCA3 copy, PSA copy and for the score of PCA3/PSA RNA, respectively...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28917266/urinary-biomarkers-in-prostate-cancer-detection-and-monitoring-progression
#12
REVIEW
Duojia Wu, Jie Ni, Julia Beretov, Paul Cozzi, Mark Willcox, Valerie Wasinger, Bradley Walsh, Peter Graham, Yong Li
Prostate cancer (CaP) is the most common cancer in men and the second leading cause of cancer deaths in males in Australia. Although serum prostate-specific antigen (PSA) has been the most widely used biomarker in CaP detection for decades, PSA screening has limitations such as low specificity and potential association with over-diagnosis. Current biomarkers used in the clinic are not useful for the early detection of CaP, or monitoring its progression, and have limited value in predicting response to treatment...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28881605/low-pca3-expression-is-a-marker-of-poor-differentiation-in-localized-prostate-tumors-exploratory-analysis-from-12-076-patients
#13
Mohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, Maria Santiago-Jiménez, Nicholas Erho, Jennifer Jordan, Kasra Yousefi, Lucia L C Lam, Tyler Kolisnik, Jijumon Chelissery, Roland Seiler, Ashley E Ross, R Jeffrey Karnes, Edward M Schaeffer, Tamara T Lotan, Robert B Den, Stephen J Freedland, Elai Davicioni, Eric A Klein, Jack A Schalken
BACKGROUND: Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic biomarker that has been clinically validated. The limitations of the diagnostic role of PCA3 in initial biopsy and the prognostic role are not well established. Here, we elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy. RESULTS: PCA3 has a bimodal distribution in both biopsy and radical prostatectomy (RP) tissues, where low PCA3 expression was significantly associated with high grade disease (p<0...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28864116/the-role-of-long-non-coding-rna-pca3-in-epithelial-ovarian-carcinoma-tumorigenesis-and-progression
#14
Yao Liu, Zhi-Hong Zong, Xue Guan, Li-Li Wang, Yang Zhao
OBJECTIVES: Ovarian carcinoma is one of the highest incidence of tumors in women, and the generation, development and prognosis of epithelial ovarian carcinoma (EOC) remains an open field of study. The role of long non-coding RNAs (lncRNAs) in epithelial ovarian carcinoma is an emerging area of research. MATERIALS AND METHODS: LncRNA PCA3 expression was determined in EOC and normal ovarian tissues by RT-PCR. Phenotypes indicative of tumor progression and aggressiveness, including cell proliferation, migration, invasion, and expression of related molecules, were analysed in EOC cell following knockdown of lncRNA PCA3 by transfection with small interfering RNA (siRNA)...
October 30, 2017: Gene
https://www.readbyqxmd.com/read/28861591/multianalyte-quantitative-competitive-pcr-on-optically-encoded-microspheres-for-an-eight-gene-panel-related-to-prostate-cancer
#15
Iraklis K Kyriakou, Konstantinos Mavridis, Despina P Kalogianni, Theodore K Christopoulos, Penelope C Ioannou, Andreas Scorilas
Nucleic acid-based tests have a profound impact in every medical discipline. Because multigene tests offer higher diagnostic accuracy and lower overall cost than single assays, they are especially useful for diseases, like prostate cancer, that present variability at the molecular level and diversity of available therapeutic interventions. We have developed a quantitative competitive PCR for an eight-gene panel, related to prostate cancer, that includes five genes of the human tissue kallikrein family (KLKs), prostate-specific membrane antigen (PSMA), prostate cancer antigen 3 (PCA3), and HPRT1 as a reference gene...
August 31, 2017: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/28853167/a-urinary-biomarker-based-risk-score-correlates-with-multiparametric-mri-for-prostate-cancer-detection
#16
Rianne J Hendriks, Marloes M G van der Leest, Siebren Dijkstra, Jelle O Barentsz, Wim Van Criekinge, Christina A Hulsbergen-van de Kaa, Jack A Schalken, Peter F A Mulders, Inge M van Oort
BACKGROUND: Prostate cancer (PCa) diagnostics would greatly benefit from more accurate, non-invasive techniques for the detection of clinically significant disease, leading to a reduction of over-diagnosis and over-treatment. The aim of this study was to determine the association between a novel urinary biomarker-based risk score (SelectMDx), multiparametric MRI (mpMRI) outcomes, and biopsy results for PCa detection. METHODS: This retrospective observational study used data from the validation study of the SelectMDx score, in which urine was collected after digital rectal examination from men undergoing prostate biopsies...
October 2017: Prostate
https://www.readbyqxmd.com/read/28807541/urinary-rna-based-biomarkers-for-prostate-cancer-detection
#17
REVIEW
Filippo Martignano, Lorena Rossi, Antonio Maugeri, Valentina Gallà, Vincenza Conteduca, Ugo De Giorgi, Valentina Casadio, Giuseppe Schepisi
Prostate cancer (PCa) is the commonest malignancy in the male population worldwide. Serum prostate specific antigen (PSA) test is the most important biomarker for the detection, follow-up and therapeutic monitoring of PCa. Defects in PSA specificity have elicited research for new biomarkers to improve early diagnosis and avoid false-positive results. This review evaluates urinary RNA-based biomarkers. Urine is a versatile body fluid for non-invasive biomarker detection in case of urological malignancies. The importance of RNA-based biomarkers has been demonstrated by the current use of PCA3, a long non coding RNA biomarker already approved by the Food and Drugs Administration...
October 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/28751581/going-viral-linking-the-etiology-of-human-prostate-cancer-to-the-pca3-long-noncoding-rna-and-oncogenic-viruses
#18
Andre A Teixeira, Serena Marchiò, Emmanuel Dias-Neto, Diana N Nunes, Israel T da Silva, Bryce Chackerian, Marc Barry, Richard C Lauer, Ricardo J Giordano, Richard L Sidman, Cosette M Wheeler, Webster K Cavenee, Renata Pasqualini, Wadih Arap
No abstract text is available yet for this article.
October 2017: EMBO Molecular Medicine
https://www.readbyqxmd.com/read/28739722/grp78-participates-in-pca3-regulated-prostate-cancer-progression
#19
Chunhua Lin, Jiahui Wang, Yanwei Wang, Peng Zhu, Xin Liu, Ning Li, Juan Liu, Luxin Yu, Wenting Wang
BACKGROUND/AIM: The human prostate cancer antigen 3 (PCA3) is a long non-coding RNA (lncRNA) commonly used as a diagnostic marker for prostate cancer (PCa). Herein we investigated the cellular function of PCA3 in PCa and its potential mechanism. MATERIALS AND METHODS: PCA3 was overexpressed in a PC3 cell line (PC3(PCA+)) and cell proliferation, migration, invasion and apoptosis were compared to those of control cells (PC3(NC)). Differentially expressed proteins were identified by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and mass spectrometry...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668854/pca3-silencing-sensitizes-prostate-cancer-cells-to-enzalutamide-mediated-androgen-receptor-blockade
#20
Emre Özgür, Ayca Iribas Celik, Emin Darendeliler, Ugur Gezer
BACKGROUND/AIM: Prostate cancer (PCa) is an androgen-dependent disease. Novel anti-androgens (i.e. enzalutamide) have recently been developed for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Evidence is accumulating that prostate cancer antigen 3 (PCA3) is involved in androgen receptor (AR) signaling. Here, in combination with enzalutamide-mediated AR blockade, we investigated the effect of PCA3 targeting on the viability of PCa cells. MATERIALS AND METHODS: In hormone-sensitive LNCaP cells, AR-overexpressing LNCaP-AR(+) cells and VCaP cells (representing CRPC), PCA3 was silenced using siRNA oligonucleotides...
July 2017: Anticancer Research
keyword
keyword
17649
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"